Advertisement


Frank A. Sinicrope, MD, on Adjuvant Treatment Strategies for Stage III dMMR Colon Cancer

2025 ASCO Annual Meeting

Advertisement

Frank A. Sinicrope, MD, of Mayo Clinic Rochester, reviews findings from the randomized Alliance A021502/ATOMIC trial, which studied standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III DNA mismatch repair–deficient (dMMR) colon cancer (LBA1). 

 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
ATOMIC was for patients with deficient mismatch repair stage 3 colon cancer. All of these patients had undergone a surgical resection with curative intent and all were found to have deficient mismatch repair tumors by immunohistochemistry. Patients were randomized 1 to 1 to FOLFOX chemotherapy plus atezolizumab given for six months, with the atezolizumab continued for an additional six months. This was compared to FOLFOX alone for six months. Atezolizumab, as we know, is an anti–PD-L1 antibody. The objective of this study was to see whether or not the immunotherapy would improve outcomes compared to chemotherapy alone. At the second interim analysis of this trial, with 75% of events, the trial was stopped. The results were reported out at a median follow-up of 37.2 months. The chemoimmunotherapy was associated with a hazard ratio of 0.5, indicating that there was a reduction in recurrence or death by 50% compared to the FOLFOX arm. So these are impressive results we regard as practice-changing, and I would comment that the treatments were well tolerated and not associated with really any adverse events that would not be expected with each of the agents. So we regard this treatment as a new standard of care for this patient population, and it really demonstrates that taking immunotherapy that we're commonly using in this population in the metastatic setting now can be moved to earlier-stage or stage 3 disease to benefit these patients also. So we think this is a very clinically meaningful result for patients, and we're very excited to continue to see if the guidelines will now be adopting this new regimen for our patients.

Related Videos

Gynecologic Cancers

Alicia Latham, MD, MS, on Using ctDNA to Detect Endometrial Cancer

Alicia Latham, MD, MS, of Memorial Sloan Kettering Cancer Center, discusses the feasibility of using Pap-derived ctDNA for the detection of sporadic and Lynch syndrome–associated endometrial cancer (Abstract 10503). 

Prostate Cancer

Praful Ravi, MBBChir, MRCP, on High-Risk Localized Prostate Cancer: Docetaxel With ADT and Radiotherapy

Praful Ravi, MBBChir, MRCP, of Dana-Farber Cancer Institute, presents findings from an ICECaP individual patient-data meta-analysis of randomized controlled trials on a treatment strategy used in high-risk localized prostate cancer (Abstract 5013). 

Breast Cancer

Giuseppe Curigliano, MD, PhD, on Patient-Reported Outcomes From EMBER-3

Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, IRCCS, University of Milano, discusses patient-reported outcomes from the phase III EMBER-3 trial, which investigated treatment with imlunestrant, investigator’s choice of standard endocrine therapy, or imlunestrant plus abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer (Abstract 1001).  

Colorectal Cancer

Christopher M. Booth, MD, on a Structured Exercise Program for Patients With Colon Cancer

Christopher M. Booth, MD, of Queen’s University, reviews findings from the randomized phase III Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE) trial, which evaluated the impact of a structured exercise program on disease-free survival in patients with stage III or high-risk stage II colon cancer (Abstract LBA3510). 

Gastrointestinal Cancer

Yelena Y. Janjigian, MD, on Gastric/GEJ Cancer: Immunotherapy Plus FLOT

Yelena Y. Janjigian, MD, of Memorial Sloan Kettering Cancer Center, presents event-free survival data from the phase III MATTERHORN trial of the PD-L1 inhibitor durvalumab plus FLOT (fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy) in patients with resectable gastric or gastroesophageal junction (GEJ) cancer (LBA5). 

Advertisement

Advertisement




Advertisement